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Abstract
Malignant thymoma is an extremely rare entity.
According to a study, the annual incidence of malignant
thymoma was estimated to be 0.15 per 100,000 person-
years. We present the case of a 42-year-old female who
came to us with a Type AB, Masaoka stage III malignant
(invasive) thymoma with widespread involvement of the
mediastinum.
Introduction
Invasive (malignant) thymomas are rare tumours,
which represent about 20-25% of all mediastinal tumours
and 50% of anterior mediastinal masses. The etiology of
these types of tumours is not known.1 In about 50% of the
patients, thymomas are detected by chance with plain-film
chest radiography. Standard primary treatment for these
types of tumours is surgical with en masse resection for
invasive tumours. Complete surgical resection is an
important prognostic factor for locally advanced malignant
thymoma.2-4 We describe the case of a 42-year-old female
who presented with an extensive stage III malignant
thymoma involving pleura, diaphragm, and phrenic nerve
invading the left lower lung and the pericardium. 
Case Report
A 42-year-old non-smoking, healthy female with no
known co-morbidities, presented to us with symptoms of
episodic left sided subcostal chest pain for 2 months
associated with backache and low-grade fever. General
physical examination was unremarkable except for basal
crepitations on the left side of the chest. 
There was no history of previous hospitalization for
any surgeries or medical problems. She was, however, being
treated for a suspected pneumonia at a local hospital.
During her work up for pneumonia, a chest x-ray was done
which revealed a lobulated radio-opaque density on the left
lower lung lobe and was subsequently referred to us. 
Chest roentgenogram showed a large soft tissue
density mass adjacent to left bronchus. CT scan with
contrast revealed an intermediate to low-density lobulated
mass in the anterior mediastinum, which was compressing
the heart and major blood vessels. The heart was pushed to
the right side across midline but no pericardial effusion was
noted. The mass was also attached to the linguila, associated
with moderate left pleural effusion. A 2cm pre-carinal node
was also visible.
MRI showed a similar picture of a lobulated, solid,
mildly enhancing anterior mediastinal mass measuring 12.5
× 11.1 × 7.9 cm however, another pleural based solid lesion
was also appreciated along the posterior aspect of left lower
lobe measuring 1.5 × 3.1 cm. Bronchoscopy demonstrated
no endobronchial lesion. The culture was negative for acid-
fast bacilli, other microorganisms and malignant cells.
Immunohistochemistry reports were positive for Thymoma
cytokeratin.
Histological analysis of CT guided trucut biopsy of
the pulmonary mass showed the tumour to be consisting of
neoplastic epithelial cells and non-neoplastic lymphocytes.
The tumour also demonstrated signs of microinvasion of the
capsule. The findings were consistent with malignant
(invasive) thymoma of mixed (lymphoepithelial) variety.
The diaphragmatic mass and left lateral pleural basal
nodules were found to be tumour deposits. Mediastinal
lymph nodes were free of tumour metastasis.
The patient underwent preoperative chemotherapy.
After the shrinkage of tumour size, posterolateral
thoracotomy for complete thymectomy plus excision of left
lung and parietal pleural masses was done through the fifth
intercostal space, and the residual tumour along with left
linguila of the lung and pericardium were removed,
however the phrenic nerve was cautiously preserved.
Postoperative course was uneventful and the patient was
discharged on seventh postoperative day.  
Discussion
Thymoma is a rare tumour arising from the
epithelium of the thymus gland but it is the most common
neoplasm of the anterior mediastinum comprising about 20-
25% of all mediastinal tumours and 50% of anterior
mediastinal masses.1 Thirty to 40 percent of these are
malignant with malignancy usually defined by the surgical
findings of invasion or the presence of intrathoracic or
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extrathoracic metastases.4 In a study conducted in US, the
overall incidence of malignant thymoma was found to be 15
per 10000000 person-years.5
Malignant thymoma is detected most frequently in
the fourth and fifth decade of life. Men and women are
equally affected. It is rare in children.6
Approximately 30% of the patients with thymoma
are asymptomatic at the time of diagnosis.4 In other cases,
the presenting clinical signs of these types of tumours may
include coughing, chest pain, and signs of upper airway
congestion. Paraneoplastic autoimmune syndromes
associated with thymoma include myasthenia gravis (MG),
polymyositis, lupus erythematosus, rheumatoid arthritis,
thyroiditis, and Sjögren's syndrome, among others. As many
as 30-40% of patients who have a thymoma  also suffer
from MG.2,4 Autoimmune pure red cell aplasia and
hypogammaglobulinemia affect approximately 5% and 5 to
10%, respectively, of patients with thymoma.6
Diagnosis is made clinically based on the
radiological findings. Laboratory blood investigations are
generally not indicated. Chest x-ray, including lateral view
can detect most thymomas. CT scan may delineate the
lesion further or detect smaller tumours and aid in
characterization of thymoma to successfully distinguish it
from other benign mediastinal tumours (especially
lymphomas and germ cell tumours). It can also reveal
features suggestive of malignancy - for instance; vascular
invasion, encasement and pleural deposits.  Biopsy is
performed in cases where there is suspicion of malignancy
in order to initiate proper treatment.6
The only treatment for resectable malignant
thymomas is complete resection and the most common
operative approach is usually median sternotomy, although
we employed a left posterolateral thoracotomy due to
pleural and diaphragmatic involvement and the need for
excision of left lower lung lobe.2,3 Total resection of a well-
encapsulated, noninvasive thymoma is usually curative and
has a risk of local recurrence of less than 2%.3 Some reports
have shown excellent long-term survival with extended
resection in patients with stage III and IV disease. Their
overall 5- and 10-year survival rates were 77% and 59%,
respectively.7 The value of incomplete resection is quite
controversial. Many authors believe that incomplete
resection has no survival or recurrence value over biopsy
alone.8 Other authors, including Mornex et al, found that
survival was better after partial resection than after biopsy
(5-year survival, 64% vs. 39%, respectively).8
Local recurrence following surgery occurs in less
than 2% of patients who have surgery for encapsulated
lesions and in 20% to 40% of those who undergo surgery for
invasive disease.2
Adjuvant radiation therapy is definitely indicated for
completely or incompletely resected stage III or IV
thymomas.2,6,8 The role of chemotherapy is yet not
established.8
Several retrospective studies have attempted to
define clinicopathologic variables that can be used to
predict prognosis in patients with thymoma. In one
multivariate analysis conducted at John Hopkins, four
factors proved to have an independent influence on overall
survival: the extent of surgical resection, the presence of
MG, the histology, and age at initial diagnosis. MG was
found to be a positive prognostic factor where as age,
gender and race failed to reach statistical significance as
independent predictors of both overall and thymoma-related
survival.6 The only variable that proved to be a significant
independent predictor of decreased thymoma-related death
was complete surgical resection independent of Masaoka
stage. These results support aggressive surgical
intervention, even in patients with advanced disease at
initial presentation. 
Conclusion
Malignant thymoma is an extremely rare entity. The
etiology of these types of tumours is not known. Standard
primary treatment is surgical with en masse resection for
invasive tumours. Adjuvant radiation therapy is indicated
for stage III and IV malignant thymomas.
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